Catalent, Inc. (NYSE:CTLT), the global leader in drug development
solutions and advanced delivery technologies for pharmaceutical,
biologic, and consumer health products, today announced that it has
appointed Jack Stahl and Rolf Classon to its Board of Directors.
Mr. Jack Stahl was President and Chief Executive Officer of Revlon, Inc.
between 2002 and 2006. Previously, he acted as President and Chief
Operating Officer of The Coca-Cola Company from 2000 to 2001. Mr. Stahl
also serves on the Boards of Coty, Inc., Delhaize Group, and the U.S.
Board of Advisors of CVC Capital. Additionally, Mr. Stahl formerly
served on the Boards of Schering-Plough Corporation and Dr Pepper
Snapple Group. He holds a Bachelor's degree in Economics from Emory
University and a Master's degree from the Wharton School of Business at
the University of Pennsylvania.
Mr. Rolf Classon was Chairman of the Executive Committee at Bayer
HealthCare AG, a subsidiary of Bayer AG, from October 2002 until his
retirement in July 2004. He served as President of Bayer Diagnostics
from 1995 to 2002 and as Executive Vice President from 1991 to 1995.
Prior to 1991, Mr. Classon held various management positions with
Pharmacia Corporation. Mr. Classon currently serves as Chairman of the
Boards of Auxilium Pharmaceuticals, Inc., Hill-Rom Corporation, and
Tecan Group Ltd., and he serves on the Board of Fresenius Medical Care.
Mr. Classon served as Vice Chairman of Auxilium Pharmaceuticals, Inc.
from March 2005 to April 2005, and he was interim Chief Executive
Officer of Hill-Rom Corporation from May 2005 until March 2006. Mr.
Classon also served as a Director on the Boards of Millipore
Corporation, Prometheus Laboratories Inc., and Enzon Pharmaceuticals,
Inc. Mr. Classon received his Chemical Engineering Certificate from the
Gothenburg School of Engineering ad a Business degree from the
Messrs. Stahl and Classon have also joined Catalent's Audit Committee,
with Mr. Stahl serving as Chair.
"We welcome both Jack and Rolf to our Board," commented John Chiminski,
President and CEO, Catalent, Inc. "Both are senior healthcare
executives, with a wealth of knowledge and experience within the sector.
We will look to draw upon their expertise as we embark on the next,
exciting stage of our Company's history."
About Catalent, Inc.
Catalent, Inc. is the leading global provider of advanced delivery
technologies and development solutions for drugs, biologics and consumer
health products. With over 80 years serving the industry, Catalent has
proven expertise in bringing more customer products to market faster,
enhancing product performance and ensuring reliable clinical and
commercial product supply. Catalent employs approximately 8,000 people,
including over 1,000 scientists, at nearly 30 facilities across 5
continents. Catalent is headquartered in Somerset, N.J. For more
information, visit www.catalent.com
Forward Looking Statements
This press release contains both historical and forward-looking
statements. All statements other than statements of historical fact are,
or may be deemed to be, forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. These
forward-looking statements generally can be identified by the use of
statements that include phrases such as "believe," "expect,"
"anticipate", "intend", "estimate", "plan", "project", "foresee",
"likely", "may", "will", "would" or other words or phrases with similar
meanings. Similarly, statements that describe our objectives, plans or
goals are, or may be, forward-looking statements. These statements are
based on current expectations of future events. If underlying
assumptions prove inaccurate or unknown risks or uncertainties
materialize, actual results could vary materially from Catalent, Inc.'s
expectations and projections. Some of the factors that could cause
actual results to differ include, but are not limited to, the following:
general industry conditions and competition; product or other liability
risk inherent in the design, development, manufacture and marketing of
our offerings; inability to enhance our existing or introduce new
technology or services in a timely manner; economic conditions, such as
interest rate and currency exchange rate fluctuations; technological
advances and patents attained by competitors; and our substantial debt
and debt service requirements that restrict our operating and financial
flexibility and impose significant interest and financial costs. For a
more detailed discussion of these and other factors, see the information
under the caption "Risk Factors" in our Prospectus dated July 30, 2014
filed with the Securities and Exchange Commission. All forward-looking
statements speak only as of the date of this release or as of the date
they are made, and Catalent, Inc. does not undertake to update any
forward-looking statements as a result of new information or future
events or developments unless required by law.
More products. Better treatments. Reliably supplied.™
[ Back To NFVZone's Homepage ]